What Longevity Really Means in Aesthetic Medicine
Ahead of CCR 2026, we spoke to two clinicians shaping how the specialty thinks about ageing, evidence and the limits of good practice
Skin longevity, regenerative medicine, biostimulation, preventative aesthetics and whole-person health are no longer fringe concepts in aesthetics. They are becoming central to how the industry thinks about ageing, treatment and patient care.
At Cosmetic Insure, we see the practical end of that change. Practitioners come to us every week wanting to add something new to their treatment menu, and the questions they ask have changed with them: less about a single procedure, more about how a whole approach to patient care fits together.
CCR reflects the same direction of travel, with medical longevity and the future of aesthetic medicine firmly on this year’s agenda. We will be there on stand E86 across both days (come to visit us at stand E86!). So ahead of the exhibition and the Medical Longevity Summit, we sat down with two clinicians leading that conversation.
The Clinicians
Dr Gaby Prinsloo is Medical Director at the iiaa, the organisation behind Environ and Advanced Nutrition Programme in the UK and Ireland. Her role sits at the point where skincare science, clinical education and regulation meet, which gives her an unusually clear view of the gap between what a product can be shown to do and what it is being marketed to do. Much of her contribution below is about closing that gap.
Dr Mayoni Gooneratne brings a different route to the same conclusions. A former NHS colorectal surgeon, she moved into functional medicine and aesthetics and now practises at the intersection of the two. She is the founder of Human Health and SkinFit, and a founder of the Society of Integrative Aesthetics, which she established because she believes the speciality should be moving towards a more holistic model of patient care. She has worked in this space for more than twelve years, and has watched the approach go from fringe to Mainstream.
The consultation is getting longer
The traditional consultation is efficient and familiar. A patient arrives with a concern, the practitioner assesses it, a treatment is chosen, and the patient returns when something else bothers them. It works. But it treats the face as a series of separate problems arriving in sequence.
Dr Gaby expects that model to give way to something with a longer horizon. “The biggest shift will be from appointment-by-appointment correction to longer-term care,” she says. Rather than treating an isolated line or area of volume loss, practitioners will plan across several years, taking account of skin quality, facial structure, biological ageing and the patient’s wider health.
The consultation becomes a conversation about how the skin and face are likely to change over time, rather than how to correct one feature today.
Dr Mayoni: treating the environment before the presentation
For Dr Mayoni, this is the whole premise of integrative aesthetics, and she is careful to define the term rather than leave it as a feeling. Within the Society of Integrative Aesthetics, it has been set out as the intersection of three disciplines: traditional aesthetics, regenerative techniques and systems biology.
“Integrative aesthetics means looking beyond just the isolated aesthetic concern and considering the patient’s overall health and biology,” she explains. “Rather than just ‘fixing’ a wrinkle or adding volume, it’s about understanding why those changes are happening in the first place.”
The clinical logic behind it is straightforward. Tissue that is inflamed, poorly nourished or healing badly will not respond to treatment in the same way as tissue that is functioning well. Optimising cell function and general health is not an add-on to the aesthetic plan; in her view, it is the foundation the plan is built on. Get that right, she argues, and treatments become “more effective, predictable and longer lasting.”
That produces a different kind of treatment plan. Rather than a sequence of isolated tweakments, each one reacting to whatever the patient noticed most recently, a genuinely personalised plan accounts for systemic health, lifestyle and long-term goals. It also makes expectations easier to manage, because patients understand how their own health is shaping the result.
Dr Gaby: What skin longevity actually means
Dr Gaby approaches the same territory through a term that has become almost unavoidable in marketing, and which she would like to see used more precisely. Clinically, skin longevity means preserving the skin’s function and resilience for as long as possible: an effective barrier, balanced immune function, stable pigmentation, good repair capacity and the dermal support that gives skin its strength and elasticity. As she puts it, “wrinkles matter to patients, but they are only one part of the picture.”
Inflammation sits at the centre of her thinking. Persistent low-grade inflammation, sometimes called inflammaging, impairs barrier recovery and contributes to the breakdown of collagen and other matrix components. Its drivers can be local, such as UV and blue light exposure or active inflammatory skin disease, or systemic, including metabolic dysfunction, smoking, chronic stress and changes in the gut-skin axis.
That changes both what an assessment looks for and the order of treatment. Alongside lines and laxity, it means paying attention to redness, sensitivity, barrier impairment, pigmentation, photodamage and healing. And it means getting the foundations right before escalating: photoprotection, evidence-based topical care, control of active skin disease and referral where wider health issues emerge.
She is careful about what the term can promise. “Skin longevity is not a promise to stop ageing,” she says. “It is a practical way to help the skin age well, using realistic goals, periodic review and no more treatment than the patient genuinely needs.”
What is happening beneath the skin
Systemic health is not wellness language borrowed for marketing purposes. Collagen production and wound healing require adequate protein, energy and micronutrients. Insulin resistance and persistently high glucose increase glycation, which affects collagen and makes remodelling harder. Poor sleep, chronic stress and smoking all increase inflammatory or oxidative stress. The gut microbiome influences immune regulation, metabolism and inflammatory signalling, all of which show up in the skin.
One presentation is now common enough to build into your consultation as standard. Patients losing weight rapidly, particularly those using GLP-1 medicines, may be nutritionally depleted in ways that directly affect outcomes. As Dr Gaby notes, inadequate protein or micronutrient intake can affect healing, muscle mass, facial appearance and skin quality.
The value of asking is diagnostic rather than advisory. A short review covering diet, sleep, stress, smoking, alcohol, weight change and weight-loss medication may explain poor healing or a response to treatment that otherwise looks inexplicable.
Knowing where your expertise ends
This is where both are most careful, and it is the section we would encourage practitioners to read twice.
A wider assessment does not mean a wider scope of practice. “This does not mean every aesthetic practitioner needs to become a longevity doctor,” says Dr Gaby. “It means recognising that the skin is an organ, and that its condition reflects more than what we apply or inject locally.” The aim is not to turn an aesthetic consultation into a general medical clinic.
Dr Mayoni would like to see more candour across the specialty on exactly this point, particularly around practitioners being honest about what they can and cannot diagnose or treat. Where the expertise is not there, the answer is referral, further training, or working as part of a multidisciplinary team. “Practitioners need to know their limits, refer appropriately, and collaborate when patients have concerns outside their expertise. This improves patient safety and outcomes, and helps build trust.”
From where we sit, that is also a risk management point. Referral is rarely the thing that generates a complaint. Treating outside your competence frequently is.
Bringing something new back from CCR?
“A new treatment or device isn’t just a new line on your price list. Before you treat, check that the specific treatment sits within your policy, that your training is documented, and that any equipment you’ve invested in is covered in its own right – the device as well as the treatment you deliver with it. More on all of this at the end of this article.”
– Stephanie Butterick BA (Hons) ACII
Why the market moved from volume to tissue quality
The growth in biostimulators and regenerative injectables reflects all of this rather than running alongside it.
Ageing is not only a loss of volume. Skin and supporting tissues change through collagen and elastin degradation, glycation, chronic inflammation, altered fat compartments, ligament laxity and bone remodelling. Volume replacement addresses one part of that, and as Dr Gaby points out, relied on too heavily it can make a face look heavier rather than healthier.
But neither clinician treats the category label as a guarantee. “‘Biostimulatory’ and ‘regenerative’ are not guarantees of efficacy,” she says, and results still depend on patient selection, anatomy, placement, dilution and technique. Her summary of the practitioner’s role is the line worth carrying around the exhibition floor: “The clinician’s job is to identify what the tissue actually needs.”
Separating evidence from enthusiasm
Both leading experts are clear that products are arriving faster than the data needed to support them, and both regard the ability to wait as a professional skill rather than a missed opportunity.
Dr Gaby applies one test, and it is worth borrowing word for word. Has the exact claim being marketed been demonstrated in people, using this product, by this route and for this indication? A plausible laboratory mechanism, she says, “is a starting point, not proof of a clinical result.”
The distinction it draws is between evidence for an ingredient and evidence for a finished product. The first supports biological plausibility. Only the second tells you what will happen in your patient.
Dr Gaby also makes a point that will not sell many stand tickets: some of the most valuable interventions remain the least fashionable. Daily photoprotection, topical vitamin A where appropriate, management of inflammatory skin disease and good nutritional support have a stronger clinical foundation than a good deal of what is newer and louder.
Dr Mayoni adds a commercial test alongside the clinical one. “I encourage all clinicians and business owners to have a clear business case for all devices, treatments and services they are thinking of adding.” A treatment coming into your clinic should pass both.
Prevention and knowing where to stop
Preventative aesthetics is growing – patients would rather maintain healthy skin gradually than wait for advanced change and seek extensive correction later.
But prevention can quietly become a reason to treat everything. Dr Gaby’s threshold is a defined aim and a favourable balance of benefit, burden and risk. The line is crossed, she says, when treatment is driven mainly by fear, trends, commercial scheduling or the belief that every normal feature requires correction.
Her test before intervening is a good one to hold any treatment plan against: be able to name the concern, explain the expected benefit, discuss the no-treatment option, and justify why acting now is better than review or observation. Psychological vulnerability, unrealistic expectations or repeated requests without a meaningful treatment target should prompt caution and, where appropriate, referral. “Restraint is an important part of good aesthetic practice.”
What this means for your clinic
If you are planning to bring something new back from CCR, there is one more question to add to the list.
A new injectable, device or service is not simply a new line on your price list. It can mean new training requirements, new clinical protocols, new consent processes, and a change to your insurance.
Our advice is the same one we give every week: talk to your insurer before you treat, not after. Do not assume that because you already hold aesthetic insurance, a new treatment is automatically covered. We may need to establish what the treatment involves, whether it sits within the scope of your existing policy, what training you hold, and whether any additional terms apply.
It is also worth thinking about the device itself, not just the treatment you deliver with it. If you are investing in new equipment, that equipment can be insured too, covering loss, theft or damage alongside the treatment liability attached to using it. Practitioners often arrange one and overlook the other.
For emerging treatments, where the evidence, regulatory position or supply route may still be developing, that conversation matters more, not less. Dr Gaby’s own advice is unambiguous: “If the regulatory documentation, evidence, supply route or indemnity position remains unclear, do not introduce the treatment until it has been resolved.”
.
Why we’re interested in longevity medicine
As specialists in medical aesthetics insurance, we are seeing increasing interest from practitioners in regenerative, longevity-focused and integrative treatment approaches, and it is creating new questions for insurers.
Insurance markets traditionally assess risk using a combination of clinical evidence, regulatory position and historical claims experience. With some emerging treatments, that history may be limited or still developing.
Our role is not to make clinical decisions. It is to understand how new treatments fit within the evolving aesthetics landscape, and what they mean from a risk, training and insurance Perspective.
That is one of the reasons we attend events such as CCR. They give us the opportunity to learn directly from clinicians, educators and industry leaders, so we can have informed conversations with insurers and help ensure appropriate insurance solutions remain available for our clients.
Say hello to us at CCR 2026
CCR 2026 takes place at ExCeL London on 1-2 October. Come and find the Cosmetic Insure team on stand E86 – we are always happy to talk through what a new treatment means for your cover.
With many thanks to Dr Gaby Prinsloo, Medical Director at the iiaa, and Dr Mayoni Gooneratne, former NHS surgeon, functional medicine doctor and a founder of the Society of Integrative Aesthetics.
This article is for general information and education only. It does not constitute clinical, regulatory or insurance advice, and it is not a recommendation of any specific treatment or product. Cover depends on the terms of your individual policy.
Share This Story, Choose Your Platform!
Cosmetic Insure Disclaimer
All the information provided in our Cosmetic Insure Treatment Guides and blog articles serves as a valuable reference and informational resource. Our intention is to offer insights that assist you in making informed choices when exploring the extensive array of non-surgical aesthetic treatments available.
Please note that this information does not constitute medical advice. Any reliance you place on the content found within the Cosmetic Insure Treatment Guides, Cosmetic Insure blog articles, or on any part of cosmeticinsure.com is done so entirely at your own discretion.
Prior to considering any non-surgical cosmetic treatment mentioned anywhere on cosmeticinsure.com, we strongly recommend that you engage in thorough consultation with a duly qualified and accredited practitioner who possesses the proper training and comprehensive insurance coverage for the specific treatment you are interested in. Neither the author of the guides or blog articles, nor the practitioner who has verified these guides, nor Cosmetic Insure, can be held responsible or liable for any loss or claims resulting from the use or misuse of cosmeticinsure.com’s content. Your safety and well-being are our utmost concern.
